Journals / Van Tıp Dergisi / 2013 / Cilt: 20 - Sayı: 2

Factor VII eksikliği olan hastada femoral cerrahide rekombinant faktör VIIa kullanımı: Bir olgu sunumu

Use of recombinant factor viia for femoral surgery in a patient with factor vıı deficiency: a case report

Pages
94–96
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As long-term response was obtained following single dose of rFVIIa in the challenge test performed to the patient, we achieved post-traumatic and perioperative control of hemorrhage at replacement dose of 25 μg/kg/6 hours.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:First identified in 1951, congenital deficiency of factor VII (FVII) is an autosomal recessive hemorrhagic diathesis leading to hemorrhagic disorder related to level of factor.
📊
Key Findings & Data:Its half-life has been reported as 2.5 to 3 hours.
💡
Conclusion & Impact:As long-term response was obtained following single dose of rFVIIa in the challenge test performed to the patient, we achieved post-traumatic and perioperative control of hemorrhage at replacement dose of 25 μg/kg/6 hours.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

First identified in 1951, congenital deficiency of factor VII (FVII) is an autosomal recessive hemorrhagic diathesis leading to hemorrhagic disorder related to level of factor. Its half-life has been reported as 2.5 to 3 hours. Today, hemorrhage control is achieved with factor VII in the individuals with deficiency of FVII. Here we present a case with congenital FVII deficiency who was hospitalized with diagnosis of supracondylar femoral fracture. As long-term response was obtained following single dose of rFVIIa in the challenge test performed to the patient, we achieved post-traumatic and perioperative control of hemorrhage at replacement dose of 25 μg/kg/6 hours.

Özet

İlk olarak 1951 yılında tanımlanmış olan konjenital faktör VII eksikliği, faktör düzeyi ile ilişkili olarak hemostaz bozukluklarına neden olan, otozomal resesif bir kanama diatezidir. Faktör VII’nin yarılanma ömrü 2.5-3 saat olarak bildirilmektedir. Kanama kontrolü günümüzde faktör VII replasmanı ile sağlanmaktadır. Burada suprakondiler femur fraktürü tanısıyla yatırılan, konjenital faktör VII eksikliği tanılı bir olgu sunuldu. Hastaya yaptığımız chellenge testi’nde tek doz sonrası rekombinant FVIIa’ya aldığımız uzun süreli cevap nedeni ile 25 μg/kg/6 saat dozunda replasman ile post travmatik ve perioperatif kanama kontrolü sağladık.

🔖

Cite This Article

DEMİR, C., ATMACA, M., TAŞDEMİR, E., ESEN, R., DİLEK, İ., ÖZBAY, M. F. (2013). Factor VII eksikliği olan hastada femoral cerrahide rekombinant faktör VIIa kullanımı: Bir olgu sunumu. Van Tıp Dergisi, Cilt: 20 - Sayı: 2, 94–96. https://ajindex.com/articles/334841

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Mansouritorgabeh H, Rezaieyazdi Z, Pourfathollah AA, Rezai J, Esamaili H. Haemorrhagic symptoms in patients with combined factors V and VIII deficiency in north-eastern Iran. Haemophilia 2004; 10(3):271-275. 2.Thompson AR. Congenital bleeding disorders from other coagulation protein deficiencies. In: Young NS, Gerson SL, High KA, editors. Clinical Hematology. Philadelphia 2006. pp. 855–866. 3.Boltin D, Boguslavski V, Goor Y, Elkayam O. Primary factor VII deficiency. Isr Med Assoc J 2008; 10(6):475-476. 4.Perry DJ. Factor VII Deficiency. Br J Haematol 2002; 118(3):689-700. 5.Mariani G, Mannucci PM, Mazzucconi MG, Capitanio A. Treatment of congenital factor VII deficiency with a new concentrate. Thromb Haemost 1978; 39(3):675-682. 6.Ragni MV, Lewis JH, Spero JA, Hasiba U. Factor VII deficiency. Am J Hematol 1981; 10(1):79-88. 7.Triplett DA, Brandt JT, Batard MA, Dixon JL, Fair DS. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood 1985; 66(6):1284-1287. 8.Bauer KA. Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis 1996; (1):155-158. 9.Dike GW, Griffiths D, Bidwell E, Snape TJ, Rizza CR. A factor VII concentrate for therapeutic use. Br J Haematol 1980; 45(1):107- 118. 10.Kuzel T, Green D, Stulberg SD, Baron J. Arthropathy and surgery in congenital factor VII deficiency. Am J Med 1988; 84(4):771-774. 11.Rivard GE, Kovac I, Kunschak M, Thöne P. Clinical study of recovery and half-life of vapor- heated factor VII concentrate. Transfusion 1994; 34(11):975-979. 12.Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O. Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia 1997; 3(3):215-218. 13.Niikura T, Nishikawa T, Saegusa Y, Fujishiro T, Yoshiya S, Kurosaka M. Total hip arthroplasty in severe congenital factor VII deficiency: successful use of recombinant activated factor VII for hemostasis. J Arthroplasty 2005; 20(3):396-400. 14.Gopalan PK, Clohisy JC, Cashen AF, Eby CS. Use of recombinant factor VIIa for hip surgery in a patient with factor-VII deficiency. A case report. J Bone Joint Surg Am 2007; 89(2):389- 391.